Atara Biotherapeutics, Inc. (ATRA) stock
ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.50+0.10 (+1.56%)
Close on Nov 17, 2026Market cap $65.25MP/E –Yield –
Atara Biotherapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Atara Biotherapeutics's operating income for the twelve months ending Jun 30, 2026 was -$14.23M, down 277.0% year over year. For fiscal 2025 it was $35.86M. The highest annual figure on record is $35.86M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.86M | – |
| FY2024 | Dec 31, 2024 | -$83.44M | – |
| FY2023 | Dec 31, 2023 | -$276.01M | – |
| FY2022 | Dec 31, 2022 | -$280.51M | – |
| FY2021 | Dec 31, 2021 | -$340.46M | – |
| FY2020 | Dec 31, 2020 | -$309.05M | – |
| FY2019 | Dec 31, 2019 | -$295.68M | – |
| FY2018 | Dec 31, 2018 | -$237.11M | – |
| FY2017 | Dec 31, 2017 | -$121.53M | – |
| FY2016 | Dec 31, 2016 | -$81.24M | – |
| FY2015 | Dec 31, 2015 | -$58.45M | – |
| FY2014 | Dec 31, 2014 | -$28.16M | – |
| FY2013 | Dec 31, 2013 | -$8.62M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.72M | -247.6% |
| Q1 FY2026 | Mar 31, 2026 | -$3.37M | -108.7% |
| Q4 FY2025 | Dec 31, 2025 | -$2.56M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.57M | – |
| Q2 FY2025 | Jun 30, 2025 | $3.20M | – |
| Q1 FY2025 | Mar 31, 2025 | $38.80M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.20M | – |
| Q3 FY2024 | Sep 30, 2024 | -$21.76M | – |
| Q2 FY2024 | Jun 30, 2024 | -$18.23M | – |
| Q1 FY2024 | Mar 31, 2024 | -$31.25M | – |
| Q4 FY2023 | Dec 31, 2023 | -$59.96M | – |
| Q3 FY2023 | Sep 30, 2023 | -$69.61M | – |
| Q2 FY2023 | Jun 30, 2023 | -$71.41M | – |
| Q1 FY2023 | Mar 31, 2023 | -$75.02M | – |
| Q4 FY2022 | Dec 31, 2022 | -$75.54M | – |
| Q3 FY2022 | Sep 30, 2022 | -$84.62M | – |
| Q2 FY2022 | Jun 30, 2022 | -$32.13M | – |
| Q1 FY2022 | Mar 31, 2022 | -$88.22M | – |
| Q4 FY2021 | Dec 31, 2021 | -$93.40M | – |
| Q3 FY2021 | Sep 30, 2021 | -$84.81M | – |
| Q2 FY2021 | Jun 30, 2021 | -$84.00M | – |
| Q1 FY2021 | Mar 31, 2021 | -$78.25M | – |
| Q4 FY2020 | Dec 31, 2020 | -$81.70M | – |
| Q3 FY2020 | Sep 30, 2020 | -$74.71M | – |
| Q2 FY2020 | Jun 30, 2020 | -$77.95M | – |
| Q1 FY2020 | Mar 31, 2020 | -$74.70M | – |
| Q4 FY2019 | Dec 31, 2019 | -$79.70M | – |
| Q3 FY2019 | Sep 30, 2019 | -$72.56M | – |
| Q2 FY2019 | Jun 30, 2019 | -$75.54M | – |
| Q1 FY2019 | Mar 31, 2019 | -$67.89M | – |
| Q4 FY2018 | Dec 31, 2018 | -$81.82M | – |
| Q3 FY2018 | Sep 30, 2018 | -$60.22M | – |
| Q2 FY2018 | Jun 30, 2018 | -$52.62M | – |
| Q1 FY2018 | Mar 31, 2018 | -$42.45M | – |
| Q4 FY2017 | Dec 31, 2017 | -$35.80M | – |
| Q3 FY2017 | Sep 30, 2017 | -$31.66M | – |
| Q2 FY2017 | Jun 30, 2017 | -$27.91M | – |
| Q1 FY2017 | Mar 31, 2017 | -$26.16M | – |
| Q4 FY2016 | Dec 31, 2016 | -$18.75M | – |
| Q3 FY2016 | Sep 30, 2016 | -$25.94M | – |
See a number that looks wrong?